Lab Test

Plasminogen Activator Inhibitor 1 Activity

PAI 1 Activity, Plasminogen Activator Inhibitor Activity

Test Codes

LabCorp #146787, EPIC: LAB6318, SOFT: XPAIA

Specimen Collection Criteria

Collect: One Light Blue-top Sodium Citrate tube.

Send specimen for processing immediately after collection.

Physician Office/Draw Specimen Preparation

Critical frozen. Immediately centrifuge and separate plasma from cells. Transfer plasma to a plastic transport tube and freeze (-20°C/-4°F or below) immediately.

Preparation for Courier Transport

Transport: 1.0 mL plasma, frozen (-20°C/-4°F or below). (Minimum: 0.5 mL)

Rejection Criteria

  • Non-citrated plasma.
  • Non-frozen specimens.
  • Specimens not collected and processed as indicated.

In-Lab Processing

Critical frozen. Immediately centrifuge and separate plasma from cells. Transfer plasma to a plastic transport tube and freeze (-20°C/-4°F or below) immediately.

Transport: 1.0 mL plasma, frozen (-20°C/-4°F or below). (Minimum: 0.5 mL) 

Storage

Specimen Stability for Testing:

Room Temperature (20-26°C or 68-78.8°F): Unacceptable
Refrigerated (2-8°C or 36-46°F): Unacceptable
Frozen (-20°C/-4°F or below): 11 days

Specimen Storage in Department Prior to Disposal:

Specimen retention time is determined by the policy of the reference laboratory. Contact the Send Outs Laboratory with any questions.

Laboratory

Sent to Laboratory Corporation of America (LabCorp), Research Triangle Park, NC.

Performed

Tuesday, Thursday.
Results are available in 4-8 days.

Reference Range

0-27 IU/mL.

Test Methodology

Enzyme Linked Immunosorbent Assay (ELISA).

Interpretation

By report.

Clinical Utility

Plasminogen Activator Inhibitor I (PAI-I) is a plasma protein that rapidly and specifically inhibits tissue Plasminogen Activator. It plays a role in the development of arterial and venous thromboembolism. Elevated levels are found in patients with Systemic Lupus Erythematosis and in patients with Hypofibrolysis. Levels are correlated with insulin release. It shows a independent risk factor for myocardial infarction and hyperinsulinemia – insulin resistance. Attempts to reduce insulin resistance also reduce levels of PAI-I. Levels of PAI-I are elevated in coronary artery disease. In patients with glucose resistance, PAI-I may be the best predictor of disease progression or coronary atherosclerosis.

CPT Codes

85415

Contacts

Last Updated

3/31/2020

Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.

 

This directory currently reflects information only for specimens collected and/or processed at the
Farmington Hills, Grosse Pointe, Royal Oak, and Troy campuses.